<DOC>
	<DOCNO>NCT02697630</DOCNO>
	<brief_summary>The purpose study see combination entinostat pembrolizumab effective treatment patient melanoma eye ( uveal melanoma ) spread sit body ( metastatic disease ) . Pembrolizumab antibody help immune system attack cancer cell . Although pembrolizumab proven clinical efficacy treat patient metastatic cutaneous melanoma , effect metastatic uveal melanoma establish . Entinostat histone deacetylase ( HDAC ) inhibitor effect cancer cell immune regulatory cell , thus potentially enhance effect immunotherapy .</brief_summary>
	<brief_title>Efficacy Study Pembrolizumab With Entinostat Treat Metastatic Melanoma Eye</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<criteria>Age 18 year . Signed date write informed consent start specific protocol procedure . ECOG PS 01 Histologically/cytologically confirm stage IV uveal melanoma Measurable disease compute tomography ( CT ) Magnetic Resonance Imaging ( MRI ) per RECIST 1.1 criterion Any number prior therapy ( include none ) , exception anticancer immunotherapy Active brain metastasis ( symptomatic and/or require corticosteroid ) leptomeningeal metastases Previous treatment anticancer immunotherapy Pregnant nursing ( lactate ) woman Medical , psychiatric , cognitive condition may compromise patient 's ability understand patient information , give informed consent , comply study protocol complete study Active autoimmune disease Immune deficiency treatment systemic corticosteroid Use investigational drug ( drug market indication ) within 28 day study drug administration Life expectancy le 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Uveal melanoma</keyword>
</DOC>